Company Overview and News

 
Goodricke bucks industry trend to acquire tea estates

2018-10-03 thehindubusinessline
The Goodricke group has many exceptions. With UK-based Camellia Plc controlling 74 per cent stake, it is the only foreign-owned tea planter left in India. Over the past five years, even as most plantation stocks suffered, Goodricke remained a consistent performer.
GOODRICKE 500166

 
D-Street Buzz: IT, pharma stocks rise led by Wipro, Dr Reddy#39;s Labs; Network18 zooms 15%

2018-09-03 moneycontrol
The Indian market is trading on a handsome note this Monday morning with the Nifty50 up 32 points at 11,712 while the Sensex is trading higher by 124 points at 38,769.
EKC BAJAJ-AUTO TCHQY 532977 532755 CADILAHC 505200 532321 532684 500477 500493 EICHERMOT BHARATFORG ASHOKLEY EXIDEIND ECQRY 517354 HINDALCO HVLQY ALBERTDA AKLD CDLYY TECHM HNDNF EXQDY 524075 GAMMONIND HAVELLS 509550 GOODRICKE 500086 AKLS 500440 500166

 
Godfrey Phillips posts Q4 net profit at Rs43 crore

2018-05-29 livemint
New Delhi:Cigarette maker Godfrey Phillips India on Tuesday reported a standalone net profit at Rs43.11 crore for the fourth quarter ended March 2018.
GOODRICKE GODFRYPHLP 500163 500166

 
NCLT wants Assam Co. bidding norms revised

2018-04-28 livemint
Kolkata: A suitor for Assam Co. India Ltd—the country’s oldest surviving and perhaps most prized tea company (in terms of assets), now going through insolvency resolution—has successfully petitioned the National Company Law Tribunal (NCLT) to dilute eligibility conditions for bids.
GOODRICKE 508494 538564 JAMESWARREN WARRENTEA 500166

 
Andrew Yule sells early harvest tea from Mim estate, Darjeeling at record price

2018-04-13 livemint
Kolkata: State-owned Andrew Yule and Co. Ltd on Friday announced that it had sold early harvest, or first flush tea from its Mim estate in Darjeeling district at Rs15,750 per kg, a record price for the garden.
526173 GOODRICKE 500166 ANDREWYU

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...